|Bid||20.88 x 1100|
|Ask||23.77 x 1000|
|Day's Range||21.94 - 23.11|
|52 Week Range||11.70 - 31.41|
|Beta (5Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2023 - Mar 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.75|
SAN DIEGO, January 31, 2023--Arcturus Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders might be concerned after seeing the share price drop...
SAN DIEGO, December 19, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.